Actavis v Eli Lilly – Summary of Supreme Court Decision of 12 July 2017

The United Kingdom Supreme Court (UKSC) today handed down its judgment in the case of Actavis UK Limited and others v Eli Lilly and Company ([2017] UKSC 46) that has significantly changed the law of patent infringement in the UK.

12 July 2017

Brenzys lists on the Australian PBS and Pfizer denied discovery of documents to establish grounds for patent infringement

As of 1 April 2017, Samsung Bioepis' Brenzys, a biosimilar to Pfizer's Enbrel (active ingredient etanercept), will join the very short list of "a-flagged" biosimilars listed on the Australian Government's Pharmaceutical Benefits Scheme (PBS).

04 April 2017

The specialization of commercial courts in patent matters, finally a reality in Madrid and Valencia (in addition to Catalonia)

In paragraph VIII of its Explanatory Memorandum, the New Patents Act 24/2015, of 24 July (NPA) explains that one of its objectives is "to combine the closeness and decentralization of the Justice with a better specialization in patent matters...

11 January 2017